DDInter1263 DDInter1676
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Naltrexone {u} may lead to a major life threatening interaction when taken with {v} Oxycodone
Naltrexone {u} (Compound) resembles {v} (Compound) Hydrocodone
Naltrexone {u} (Compound) resembles {v} (Compound) Butorphanol
Naltrexone {u} (Compound) treats {v} (Disease) alcohol dependence
Naltrexone {u} (Compound) binds {v} (Gene) OPRD1
Naltrexone {u} (Compound) upregulates {v} (Gene) TSC22D3
Naltrexone {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Antagonists
Naltrexone {u} (Compound) downregulates {v} (Gene) IER3
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorzoxazone
Naltrexone may lead to a major life threatening interaction when taken with Oxycodone
Naltrexone (Compound) resembles Hydrocodone (Compound)
Naltrexone (Compound) resembles Butorphanol (Compound)
Naltrexone (Compound) treats alcohol dependence (Disease)
Naltrexone (Compound) binds OPRD1 (Gene)
Naltrexone (Compound) upregulates TSC22D3 (Gene)
Naltrexone (Compound) is included by Opioid Antagonists (Pharmacologic Class)
Naltrexone (Compound) downregulates IER3 (Gene)
Naltrexone (Compound) causes Dyspnoea (Side Effect)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone